<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04970407</url>
  </required_header>
  <id_info>
    <org_study_id>D-FR-52120-279</org_study_id>
    <secondary_id>2021-000802-14</secondary_id>
    <nct_id>NCT04970407</nct_id>
  </id_info>
  <brief_title>A Comparative Study to Evaluate the Effects and Mechanism of Action of Dysport®, Botox® and Xeomin® in the Extensor Digitorum Brevis Model in Healthy Adult Male Participants</brief_title>
  <official_title>A Phase I, Randomised, Double-blind, Parallel-group, Single-centre Comparative Study to Evaluate the Pharmacodynamic Profile of Dysport®, Botox®, and Xeomin® in the Extensor Digitorum Brevis (EDB) Model in Healthy Adult Male Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study aimed at comparing the pharmacodynamic profile (including duration of action) of three&#xD;
      commercialized toxins by measuring the action potential of the injected muscle (extensor&#xD;
      digitorum brevis)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 6, 2021</start_date>
  <completion_date type="Anticipated">June 3, 2022</completion_date>
  <primary_completion_date type="Actual">August 26, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CMAP total amplitude measured as relative change from Baseline (%)</measure>
    <time_frame>week 28.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CMAP total amplitude measured as relative change from Baseline (%).</measure>
    <time_frame>Week 40.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of recovery of CMAP total amplitude, defined as total amplitude return to at least 85% of the Baseline value.</measure>
    <time_frame>Week 28.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of recovery of CMAP total amplitude.</measure>
    <time_frame>Week 40.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of action defined as first timepoint where EDB CMAP total amplitude is 85% or lower than the Baseline value.</measure>
    <time_frame>From baseline to week 40.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response defined as time period between time to onset and time to recovery.</measure>
    <time_frame>From baseline to week 40.</time_frame>
    <description>Time to recovery is defined as the first timepoint (post time to onset of action and assuming that % of baseline value keeps on decreasing) where EDB CMAP total amplitude returns to at least 85% of the baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal inhibition (maximal effect) reached.</measure>
    <time_frame>From baseline to week 40.</time_frame>
    <description>Maximal Effect for each participant is defined as the maximal measured inhibition of CMAP amplitude of stimulated EDB. Maximal Effect will be analysed descriptively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximal effect on the CMAP total amplitude of stimulated EDB.</measure>
    <time_frame>From baseline to week 40.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type, incidence and severity of TEAEs, SAEs, AEs (or SAEs) leading to withdrawals</measure>
    <time_frame>From baseline to week 40.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Dysport®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 Units (U) Intramuscular (IM) injection at day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Botox®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>16U IM at day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xeomin®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>16U IM at day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Botulinum toxin type A</intervention_name>
    <description>Intramuscular Injection, concentration 300 units (U)</description>
    <arm_group_label>Dysport®</arm_group_label>
    <other_name>abobotulinumtoxinA (Dysport®)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Botulinum toxin type A</intervention_name>
    <description>Intramuscular Injection, concentration 50 U</description>
    <arm_group_label>Botox®</arm_group_label>
    <other_name>onabotulinumtoxinA (Botox®)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Botulinum toxin type A</intervention_name>
    <description>Intramuscular Injection, concentration 50 U</description>
    <arm_group_label>Xeomin®</arm_group_label>
    <other_name>incobotulinumtoxinA (Xeomin®)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant must be between18 to 65 years of age inclusive, at the time of signing the&#xD;
             informed consent&#xD;
&#xD;
          -  Participants who are overtly healthy as determined by medical evaluation including&#xD;
             medical history, physical examination, laboratory tests, vital signs and cardiac&#xD;
             monitoring&#xD;
&#xD;
          -  A body mass index (BMI) within the range 18 and 30 kg/m2 (inclusive).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any medical condition that may put the participant at risk with exposure to BoNT,&#xD;
             including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral&#xD;
             sclerosis, or any other disease that might interfere with neuromuscular function&#xD;
&#xD;
          -  Previous treatment with botulinum toxin (BoNT) (any serotype) during the past 6 months&#xD;
&#xD;
          -  Known hypersensitivity to any of the components of the Dysport/ Botox/ Xeomin&#xD;
             formulation (which includes human serum albumin, lactose, sucrose) or allergy to cow's&#xD;
             milk protein&#xD;
&#xD;
          -  Use of agents that could interfere with neuromuscular transmission, including calcium&#xD;
             channel blockers, penicillamine, aminoglycosides, lincosamides, polymixins, magnesium&#xD;
             sulphate, anticholinesterases, succinylcholine and quinidine&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ipsen Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mac Research Clinical research Unit</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 2, 2021</study_first_submitted>
  <study_first_submitted_qc>July 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2021</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>incobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Where patient data can be anonymised, Ipsen will share all individual participant data that underlie the results reported in the published journal article with qualified researchers who provide a valid research question. Study documents, such as the study protocol and clinical study report, are not always available.</ipd_description>
    <ipd_time_frame>Data are available beginning 6 months and ending 5 years after the publication of the findings in a journal; after this time, only raw data may be available.</ipd_time_frame>
    <ipd_access_criteria>Proposals should be submitted to DataSharing@ipsen.com and will be assessed by a scientific review board.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

